Results 171 to 180 of about 121,509 (248)

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma. [PDF]

Curr Oncol
Mozessohn L, Villeneuve PJA, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung MC, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW.   +17 more
europepmc   +1 more source

Biomaterial‐Integrated Electroporation for Therapeutic Delivery: From Gene Editing to Tumor Ablation and Immune Modulation

Small, EarlyView.
Biomaterial‐integrated electroporation establishes a programmable therapeutic interface that coordinates electric‐field modulation, transient or irreversible membrane permeabilization, cargo stabilization, and immune remodeling. This Review highlights how nanocarriers, hydrogels, and bioelectronic interfaces expand electroporation from conventional ...
Binbin Ji, Zhuozhuo Wu, Yuyue Jiang, Xiaoyu Liu, Jingfeng Li, Fengkuo Xu, Chaojie Li, Qungang Shan, Ziyin Wang, Junhao Wang, Wei Huang, Yaping Zhuang, Wenguo Cui, Zhongmin Wang   +13 more
wiley   +1 more source

Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion. [PDF]

Brain Behav Immun Health
Stollenwerk TM, Barnett ME, Steineck AS, Shah NN, Knight JM.   +4 more
europepmc   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy. [PDF]

Ther Adv Neurol Disord
Lasocki A, Harrison SJ, Dickinson M, Kalincik T.   +3 more
europepmc   +1 more source

Reverse‐Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy

Small, EarlyView.
Bioinspired triglyceride‐ceramide lipid nanoparticles were reverse‐engineered from cytokine‐sequestering plant‐derived nanoparticles to capture pathological inflammatory mediators through protein corona formation. Dexamethasone‐loaded TCNPs combine extracellular cytokine sequestration with intracellular immunomodulation, reducing IL‐6, TNF‐α, and NF‐κΒ
Junsik J. Sung, Gargi Yogesh Digholkar, Ryan M. Pearson   +2 more
wiley   +1 more source

A strategic approach to managing Immune Effector Cell-Associated Hematotoxicity (ICAHT) during chimeric antigen receptor T-cell therapy. [PDF]

Blood Res
Yoon SE.
europepmc   +1 more source

Delafloxacin suppresses DEPDC1 expression and induces G2/M arrest in non‐small cell lung cancer cells: A drug repurposing study

Smart Molecules, EarlyView.
This study presents Delafloxacin repurposed as a DEPDC1‐targeting therapeutic aiming to suppress lung cancer progression. It highlights a novel strategy for lung cancer treatment with potential clinical applications. Abstract Emerging evidence highlights the oncogenic role of the Dishevelled, Egl‐10, and Pleckstrin domains containing 1 (DEPDC1) gene in
Noman Ali, Farishta Shafiq, Mishal Iftikhar, Muhammad Shahzad Zafar, Muhammad Shoaib   +4 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Kidney Med
Shivaraj K, Mamlouk O, Tchakarov A, Patel K, Abudayyeh A.   +4 more
europepmc   +1 more source